The Scientist profiles Mireille Gingras' company, HUYA Bioscience International, which focuses on finding early-stage drug compounds from China. HUYA, the article says, has a codevelopment model in which it licenses the compounds for development for Western markets and the Chinese company retains the rights to the Chinese market.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.